The most common grade 3 or worse events were hand-foot syndrome ( 28 [ 31 % ] in the bevacizumab and capecitabine group vs none in the bevacizumab alone group ) , hypertension ( eight [ 9 % ] vs three [ 3 % ] ) , and proteinuria ( three [ 3 % ] vs four [ 4 % ] ) .